RemeGen Q1 Profit Of ¥328m Revives Bullish Narratives On Biotech Turnaround

RemeGen (SEHK:9995) opened 2026 with Q1 revenue of C¥656.2 million and basic EPS of C¥0.58, following a trailing twelve month stretch that produced total revenue of C¥3.4 billion and basic EPS of C¥2.33. The company has seen quarterly revenue move from C¥508.0 million in Q4 2024 to C¥526.0 million in Q1 2025, then to C¥656.2 million in Q1 2026. EPS shifted from a loss of C¥0.74 in Q4 2024 to a loss of C¥0.46 in Q1 2025 and then to a profit of C¥0.58 in the latest quarter, setting up a results season where the quality and durability of margins are front of mind for investors. See our full analysis for RemeGen.With the headline numbers on the table, the next step is to see how this earnings profile lines up against the key RemeGen narratives that investors have been following and where those stories might need updating. Curious how numbers become stories that shape markets? Explore Community Narratives TTM net income turns to ¥1.3b profit Over the last twelve months, RemeGen moved from a net loss of ¥1.5b in Q4 2024 to trailing twelve month net income of ¥1.3b, with trailing EPS at ¥2.33 compared with a trailing loss per share of ¥2.73 a year earlier. What stands out for the bullish view is that profitability on a trailing basis coincides with revenue of ¥3.4b over the same period. Critics highlight that a high level of non cash earnings is flagged as a major risk, so investors may want to compare this ¥1.3b profit with operating cash flow and not just the income statement. Revenue forecasts at 14.9% vs 5.78% EPS Forecasts indicate revenue growth of about 14.9% per year while EPS is projected to rise at about 5.78% per year. This contrasts with the recent shift from a trailing loss per share of ¥2.73 in Q4 2024 to trailing EPS of ¥2.33 in Q1 2026. For a bullish narrative that focuses on growth, the tension is that revenue is expected to rise faster than earnings. The major risk flag around non cash earnings means investors may want to check whether the ¥656.2m Q1 2026 revenue and ¥328.0m net income are being converted into cash or whether some of that profit is tied up in accounting adjustments rather than in cash that can fund ongoing development. P/E of 37.8x and price below DCF fair value RemeGen trades at HK$100.10 per share with a P/E of 37.8x, compared with an Asian biotech industry average P/E of 39.6x and a peer average of 64.7x. The current price sits about 12.4% below a stated DCF fair value of HK$114.32. Skeptics may point to the major risk flag on non cash earnings and argue that even a 37.8x P/E could be demanding. Supporters can counter that the combination of a positive trailing EPS of ¥2.33, a shift to ¥1.3b of trailing net income, and a share price that is below the DCF fair value leaves room for investors who are comfortable focusing on the pipeline to weigh that valuation against the quality of those earnings. Bulls and skeptics are clearly looking at the same numbers in very different ways, so it can help to see how other investors interpret this mix of valuation and profit quality in real time through Curious how numbers become stories that shape markets? Explore Community Narratives. Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on RemeGen's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. With sentiment clearly split between the recent profit turnaround and questions about earnings quality, it makes sense to look through the numbers yourself and decide quickly where you stand, then weigh up the 3 key rewards and 2 important warning signs. See What Else Is Out There RemeGen’s earnings story leans heavily on non cash items and a relatively high P/E, which raises questions about the consistency and resilience of its profit profile. If you want companies where balance sheet strength and fundamentals do more of the talking than accounting adjustments, start comparing ideas with the solid balance sheet and fundamentals stocks screener (391 results) today. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.